DailyIQ
|
Sector:Basic MaterialsAll sectors
Last updated 5 minutes ago

CTVA·Corteva, Inc.

$.
+. (+.%)
After Hours
High
$85.97
Open
$83.99
Market Cap
57.48B
52W High
$87.69
Low
$83.23
P. Close
$85.70
P/E
49.47
52W Low
$60.53
Fwd P/E
20.78
DailyIQ Est.
$92.02
Technical Score (1D)
91
BUY
News Sentiment
50
MIXED
The latest analysis questions Corteva’s valuation as the company nears the spin‑off of its Vylor seed and genetics unit, noting that a discounted‑cash‑flow model still shows upside while earnings multiples imply a premium, creating uncertainty for the next trading week. This valuation ambiguity matters because the impending separation could split earnings and cash flows, potentially shifting the company’s risk profile and affecting short‑term liquidity expectations. Traders should watch the company’s earnings guidance for 2025 to see how the spin‑off is reflected in projected cash flows and whether the DCF upside is realized. In parallel, Corteva’s partnership with Arevo to launch the Arginex Soy seed‑applied nutrition system has completed multi‑stage validation and aligns with existing application workflows, positioning the firm to capture a growing demand for sustainable crop inputs. The introduction of Arginex Soy may boost revenue in the soybean seed treatment segment, so monitoring farmer uptake and any regulatory approvals in the next few weeks will be key. Mizuho’s recent upgrade to an Outperform rating and the lift of the price target to $96 reflects confidence in Corteva’s crop‑protection portfolio, suggesting that analysts expect continued earnings growth despite the spin‑off. Analysts will likely revisit the valuation once the company releases its Q4 2024 earnings, so watch the earnings release date and any commentary on the separation timeline. The company’s board changes, including the appointment of Greg Page as independent chair and the establishment of a nine‑member board for the future crop‑protection entity, signal a focus on governance and operational efficiency ahead of the 2026 spin‑off. Finally, the Supreme Court ruling that removed a legal barrier for pesticide manufacturers last month may still influence the company’s market share trajectory, so keep an eye on any subsequent regulatory updates that could affect pesticide approvals in the coming weeks.
Earnings Summary
CTVA operates as a global agricultural inputs company that supplies seed genetics and crop protection products to farmers worldwide, positioning it within the basic materials sector. Over the past six quarters, Corteva has delivered mixed earnings performance: EPS exceeded estimates in five of the six periods, with a notable miss in Q4 2025 when earnings fell to $0.22 versus an estimate of $1.17; revenue, however, has been volatile, rising from $3.978 billion in Q4 2024 to a peak of $6.456 billion in Q2 2025 before falling to $3.91 billion in Q4 2025 and rebounding to $4.905 billion in Q1 2026. Historically, the company has shown strong EPS growth in the first three quarters of 2025, but the sharp revenue decline in Q4 2025 highlights sensitivity to market conditions and product mix shifts. Recent corporate actions include the impending spin‑off of Vylor into a standalone crop‑protection entity, which introduces valuation uncertainty and could reshape investor expectations; Morningstar’s forthcoming analyst report may further influence market perception; and leadership appointments for the new entity signal a strategic focus on differentiated innovation. Investors should watch for the formal spin‑off announcement, guidance on the new crop‑protection company’s growth prospects, and any regulatory approvals that could delay the transition, as these factors will materially affect earnings forecasts and valuation multiples in the next trading cycle. Additionally, the company’s recent investment in advanced seed traits and the launch of new herbicide formulations could provide a tailwind for future revenue streams, but the impact will become clearer after the next earnings release.

EPS

EstBeatMiss
$-0.87$0.00$0.88$1.75$2.62Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.22 - -
Q1'26$1.18$1.50+27.1%
Q4'25$1.17$0.22-81.3%
Q3'25$-0.47$-0.23+50.6%
Q2'25$1.88$2.20+17.1%
Q1'25$0.88$1.13+28.2%

Revenue

EstBeatMiss
$3.5B$4.4B$5.3B$6.2B$7.1BQ1'25Q2'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$6.7B - -
Q1'26$4.6B$4.9B+5.8%
Q4'25$4.6B$3.9B-15.8%
Q3'25 - - -
Q2'25 - $6.5B -
Q1'25 - $4.4B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

CTVA Stock Snapshot

CTVA is currently trading at $85.29, giving Corteva, Inc. a market cap of 57.48B and a P/E ratio of 49.5. Today's range spans $83.23–$85.97, with shares opening at $83.99 and moving down $0.41 (0.5%) from the prior close. DailyIQ's technical score sits at 91/100 (BUY) with a news sentiment reading of 50/100.

Over the past year CTVA has traded between $60.53 and $87.69 - the current price is +40.9% off the 52-week low and -2.7% from the high. 32 analysts cover the stock with a Buy consensus and a mean 12-month target of $90.15 (range $77.00–$100.00), implying upside of +5.7%.

The bullish case for CTVA is built on complementary signals: 91/100 technical score, BUY designation, and neutral sentiment at 50/100. At $85.29 (near 52-week highs within $60.53–$87.69), the stock is at a capitalization - 57.48B - where active managers can build meaningful positions without moving the market. (P/E: 49.5) That combination of signal quality and position-buildability makes this one of the more actionable large-cap setups in Basic Materials.

What makes CTVA's BUY setup (91/100) particularly actionable at 57.48B in Basic Materials capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $85.29 (near 52-week highs in $60.53–$87.69), with sentiment running neutral at 50/100, the setup rewards conviction-sized positioning more than it does speculative small bets.